© 2023 Cellaïon
We aim to repair tissues and regenerate organs using cell signaling technology
Our first target is the liver space. The liver is a critical organ of the body that is responsible for an array of functions. Any downfall of its functioning leads to failure of other vital organs and ultimately death.
With HepaStem®, Cellaïon aims to stop the progression of chronic liver disease, control inflammation, stop fibrous tissue accumulation in the liver and eventually allow organ recovery and regeneration of the liver.
Our lead product, HepaStem®, acts as a therapeutic cargo, delivering to the liver and inflamed tissues appropriate immunomodulatory signals with specific anti-inflammatory, anti-fibrotic and regenerative activities.
HepaStem® is being developed to cover a broad spectrum of liver diseases, from life-threatening acute-on-chronic liver failure (ACLF) and acute alcoholic hepatitis (AAH) to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH).
More than 100 patients have already received HepaStem®, which is easily administered by simple peripheral vein infusion. The very high safety profile of HepaStem® is supported by data accumulated over more than 10 years of follow-up.
Our proof-of-concept Phase IIb trial in ACLF is ongoing in many European countries and will be further extended into Latin America.
ACUTE-ON-CHRONIC LIVER FAILURE
Acute-on-chronic liver failure (ACLF) is a well-recognized clinical entity affecting patients with chronic liver disease and characterized by a sudden deterioration of the liver followed by the failure of other vital organs, such as kidney, brain, lung or heart. ACLF has a mortality ranging from 42% to 75% at 3 months.
Progressive non-alcoholic steatohepatitis (NASH) is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD). NASH is closely related to the triple epidemic of obesity, hyperlipidemia and type 2 diabetes. The chronic fat deposits can induce liver injury and sustained inflammation. NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis or liver cancer.
Acute Alcoholic hepatitis
Acute alcoholic hepatitis (AAH) is the inflammation of the liver caused by excessive consumption of alcohol. It is a syndrome characterized by rapid onset of jaundice, malaise, tender hepatomegaly, and systemic inflammatory response. AAH can be sudden and is highly fatal, with a mortality above 50% at one year.
ACUTE DECOMPENSATED CIRRHOSIS
Acute decompensation of cirrhosis (AD) is defined as an acute deterioration of the liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome and/or variceal hemorrhage. Patients with AD can develop ACLF.
Do you want to know more?
Send us an email
QA ANALYST – GcP
Cellaïon SA is currently hiring a QA Analyst – GcP.
– Writing of general quality system procedures to support business objectives and comply with regulatory requirements for clinical, production, logistics, QA and QC activities.
– Review and evaluate production batch and QC files (batch records, certificates of analysis and compliance, etc.) prior to the release of clinical batches.
– Manage and update quality assurance system documents.
More Info? Please, download the Job description!
A new article on the Multi-Target Effect of HALPCs in the NASH STAM model has recently been published in Cells Journal. “Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model”. Cells is an international, peer-reviewed, open access journal of cell biology, molecular biology, and biophysics This peer-reviewed publication recognizes HALPCs as part of the most recent advances in liver repair strategies. This article is the first to show the results of the in vitro and in vivo properties of HALPCs.
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation
Phase I/II Trial of Liver–derived Mesenchymal Stem Cells in Pediatric Liver–based Metabolic Disorders
The new Walloon company Cellaïon makes its first closing.
Cellaion SA announces a total fundraising of EUR 23 million in 2022.
Cellaion SA announces the arrival of Walid Abi-Saab in its Board of Directors, the hiring of Griet Goddemaer to lead clinical development and the green light from the DSMB for the continuation of ACLF- Dheliver Clinical trial.